学术论文
Xie T, Feng Q, Li Z et al. Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review,Hered Cancer Clin Pract,9;19(1):7.
Peng Z, Hou X, Huang Y, Xie T, et al. Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China,BMC Cancer,20(1):990.